(Q33347065)

26 July 2017

title

Phase II trial of ZD0473 as second-line therapy in mesothelioma (English)

1 reference

26 July 2017

main subject

phase II clinical trial

0 references

author name string

Giaccone G

1

1 reference

26 July 2017

O'Brien ME

2

1 reference

26 July 2017

Byrne MJ

3

1 reference

26 July 2017

Bard M

4

1 reference

26 July 2017

Kaukel E

5

1 reference

26 July 2017

Smit B

6

1 reference

26 July 2017

publication date

1 December 2002

1 reference

European Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

38 Suppl 8

1 reference

26 July 2017

page(s)

S19-24

1 reference

Treatment of malignant mesothelioma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Continuing increase in mesothelioma mortality in Britain.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Mesothelioma: new concepts in diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Management of malignant pleural mesothelioma: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

GlutathioneS-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Chemotherapy in malignant mesothelioma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

A review of chemotherapy trials for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Weekly high-dose cisplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980018-1

7 January 2021

10.1016/S0959-8049(02)80018-1

Identifiers

DOI

1 reference

26 July 2017

1 reference